New pharmacologic therapies in gastrointestinal disease.
Many gastrointestinal diseases remain poorly responsive to therapies, and even in the cases of conditions for which there are many effective drugs, there is still considerable room for improvement. This article is focused on drugs for digestive disorders that have entered the marketplace recently, or are expected to reach the marketplace within the next 1 to 2 years. Although advances have been made in understanding gastrointestinal motility, visceral pain, mucosal inflammation, and tissue repair, the major gastrointestinal diseases remain as significant therapeutic challenges.
Farncombe Family Digestive Health Research Institute, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
John L
JL
Wallace
Jose G P
JG
Ferraz
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D003248:Constipation / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005744:Gastric Acid / Q000378:metabolism*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D011188:Potassium / Q000378:metabolism; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D012778:Short Bowel Syndrome / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D017366:Serotonin Receptor Agonists; D011188:Potassium